Teoretisk er dosisjustering ikke nødvendig hos patienter med nyreinsufficiens eller leversygdom, men disse patienter skal kontrolleres tæt og behandlingshyppigheden reduceres, eller behandlingen seponeres, hvis de får uønskede virkninger.
On a theoretical basis, no dosage adjustment is necessary in patients with renal insufficiency or liver disease, but these patients should be closely monitored and treatment frequency reduced, or withdrawn, if they experience adverse effects.